WORCESTER, Mass.--(BUSINESS WIRE)--
Or-Genix Therapeutics, Inc. today announced that Cristina Griffin has joined as Chief Business Officer, a newly created position. She joins from Cantabria Labs in Madrid, Spain where she held the role of Managing Director of Corporate Development for 15 years.
Cristina has more than 20 years of experience as a global strategist and corporate development executive. Her career has extended across Europe, North America, and Latin America where she has directed over twenty mergers and acquisitions projects with a focus in pharmaceuticals, biotech, aesthetic dermatology and consumer healthcare. Cristina’s vast experience includes corporate strategy, equity financing, high margin product innovation, global branding and strategic alliance building.
“We are pleased to welcome Cristina to our management team. She brings operational excellence and experience to our company as we move our platforms of paradigm shifting skincare and woman’s healthcare products into global markets,” said Dr. Yael Schwartz, President and CEO of Or-Genix. “Her background in R&D and strategic development combined with an innovative, entrepreneurial mindset will be advantageous as we continue to optimize and expand our reach into products related to skin and mucous membrane changes during menopause and other underserved needs in dermatology,” added Dr. Schwartz.
“I am honored and inspired to join such an intrepid and innovative company,” said Ms. Griffin.
“The Or-Genix portfolio will challenge the treatment norms in dermatology and woman’s healthcare as we know them. I look forward to forging new partnerships and working alongside the leadership team to bring our novel solutions to global markets as quickly as possible.”
Cristina received her BA from the University of Wisconsin, her MA from St. John’s College, Maryland and her MBA in Global Strategic Management from Macquarie Graduate School Management, NSW, Australia.
About Or-Genix Therapeutics
Or-Genix is a Worcester, MA based research and development company focused on safe and effective topical, rapidly biodegradable pharmaceuticals and cosmeceuticals for both the professional and non-professional woman’s healthcare and dermatology markets. To learn more, please visit http://or-genixtherapeutics.com
Yael Schwartz, PhD